| Literature DB >> 35486660 |
Zerrin Isik1, Asım Leblebici2, Ezgi Demir Karaman3, Caner Karaca2, Hulya Ellidokuz4, Altug Koc5, Ender Berat Ellidokuz6, Yasemin Basbinar7.
Abstract
Adenomatous polyps of the colon are the most common neoplastic polyps. Although most of adenomatous polyps do not show malign transformation, majority of colorectal carcinomas originate from neoplastic polyps. Therefore, understanding of this transformation process would help in both preventive therapies and evaluation of malignancy risks. This study uncovers alterations in gene expressions as potential biomarkers that are revealed by integration of several network-based approaches. In silico analysis performed on a unified microarray cohort, which is covering 150 normal colon and adenomatous polyp samples. Significant gene modules were obtained by a weighted gene co-expression network analysis. Gene modules with similar profiles were mapped to a colon tissue specific functional interaction network. Several clustering algorithms run on the colon-specific network and the most significant sub-modules between the clusters were identified. The biomarkers were selected by filtering differentially expressed genes which also involve in significant biological processes and pathways. Biomarkers were also validated on two independent datasets based on their differential gene expressions. To the best of our knowledge, such a cascaded network analysis pipeline was implemented for the first time on a large collection of normal colon and polyp samples. We identified significant increases in TLR4 and MSX1 expressions as well as decrease in chemokine profiles with mostly pro-tumoral activities. These biomarkers might appear as both preventive targets and biomarkers for risk evaluation. As a result, this research proposes novel molecular markers that might be alternative to endoscopic approaches for diagnosis of adenomatous polyps.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35486660 PMCID: PMC9053805 DOI: 10.1371/journal.pone.0267973
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1An overview of the study.
Datasets used in the study.
| GEO Accession | Normal colon | Polyp | Training Set | Validation Set |
|---|---|---|---|---|
| GSE4107 | 10 |
| ||
| GSE4183 | 8 | 15 |
| |
| GSE8671 | 32 | 32 |
| |
| GSE9348 | 12 |
| ||
| GSE10714 | 3 | 5 |
| |
| GSE13471 | 4 |
| ||
| GSE15960 | 6 | 6 |
| |
| GSE18105 | 17 |
| ||
| GSE37364 | 38 | 29 |
| |
| GSE68468 | 55 | 51 |
| |
|
| 92 | 58 | ||
|
| 93 | 80 | ||
|
| 185 | 138 |
Fig 2Network topology analysis for various soft thresholds.
The left panel shows the scale-free fit index (y-axis) as a function of the soft threshold value (x-axis); the right panel shows the average connectivity (y-axis) as a function of the soft threshold value (x-axis).
Fig 3Correlation matrix resulting from WGCNA applied on the training dataset.
Here, each cell indicates the Pearson correlation and p-value resulting from the association between the respective module eigengenes (row) and phenotype (column).
Selected significant modules and the number of genes obtained on the dataset.
| Module number | Number of genes in the module |
|---|---|
| m19 | 205 |
| m20 | 517 |
| m21 | 35 |
|
|
|
Performance comparison of clustering algorithms.
| Evaluation Metric | MCL(R) | FN | Spectral | MCL(Python) |
|---|---|---|---|---|
| Modularity | 0.146 | 0.364 | 0.327 | 0.213 |
| Silhouette | 0.004 | 0.023 | 0.019 | 0.021 |
| Average_BHI | 0.251 | 0.283 | 0.262 | 0.200 |
| Average_WangBP | 0.471 | 0.479 | 0.461 | 0.362 |
| Average_WangMF | 0.571 | 0.617 | 0.596 | 0.411 |
Considering both internal and biological evaluation metrics, it was seen that the FN and Spectral algorithms generally provided better clustering results. The submodules detected by these algorithms were re-evaluated with individual BHI, Wang-BP Wang-MF metrics. First of all, submodules with the highest BHI, Wang-BP, Wang-MF values were selected, then the presence of differentially expressed genes in the relevant submodule was considered.
Summary of significant submodules detected by the best performing FN and Spectral clustering algorithms.
| Clustering Algorithm | Submodule No | Number of Genes | BHI score | Wang_BP | Wang_MF | Number of downregulated genes | Number of upregulated genes |
|---|---|---|---|---|---|---|---|
| FN | 2 | 116 | 0.317 | 0.337 | 0.654 | 14 | 0 |
| 3 | 92 | 0.158 | 0.299 | 0.475 | 32 | 1 | |
| 4 | 39 | 0.083 | 0.246 | 0.406 | 14 | 1 | |
| 5 | 29 | 0.393 | 0.441 | 0.697 | 5 | 0 | |
| 7 | 43 | 0.161 | 0.308 | 0.526 | 8 | 1 | |
| 9 | 17 | 0.367 | 0.569 | 0.741 | 2 | 0 | |
| 10 | 11 | 0.427 | 0.718 | 0.849 | 2 | 0 | |
| 24 | 4 | 0.500 | 0.740 | 0.779 | 0 | 0 | |
| 1 | 128 | 0.307 | 0.333 | 0.624 | 20 | 1 | |
| Spectral | 6 | 7 | 0.500 | 0.701 | 0.724 | 2 | 0 |
| 12 | 13 | 0.436 | 0.694 | 0.844 | 3 | 0 | |
| 14 | 7 | 0.500 | 0.559 | 0.726 | 0 | 0 | |
| 19 | 18 | 0.422 | 0.449 | 0.788 | 3 | 0 | |
| 20 | 38 | 0.100 | 0.311 | 0.557 | 10 | 0 | |
| 28 | 44 | 0.209 | 0.263 | 0.463 | 21 | 1 |
Fig 4The gene-term graph in which the up / down regulated genes of the terms that are significant terms (A. KEGG pathway, B. Cancer Hallmark term, and C. GO-BP) for the 3rd module of the FN algorithm.
Fig 5The gene-term graph in which the up / down regulated genes of the terms that are significant terms (A. KEGG pathway, B. Cancer Hallmark term, and C. GO-BP) for the 1st module of the Spectral algorithm.
The results of drug screening that targets biomarker proteins identified a result of clustering analysis.
The expression type column shows gene expression change of the gene. The action type was chosen according to the expression status of a target.
| Target | Expression Type | Compound | Action Type | Compound Description |
|---|---|---|---|---|
| GPR18 | Down | Arachidonoyl Glycine | Agonist | Endogenous agonist |
| Down | Cannabidiol | Agonist | Active cannabinoid used as an adjunctive treatment | |
| Down | Anandamide | Agonist | ||
| CSF2RB | Down | Sargramostim | Agonist | Immunostimulator for white blood cells as a chemotherapy drug |
| IL10RA | Down | Interleukin-10 | Agonist | Anti-inflammatory cytokine |
| TLR4 | Up | Resatorvid | Antagonist | Suppresses production of inflammatory mediators |
| Up | Eritoran Tetrasodium | Antagonist | Toll-like receptor 4 inhibitor. |